Glaxosmithkline Pharmaceuticals Ltd vs Onesource Specialty Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2120 as of 12 Jun 15:30 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 37.3 on March 2026 . This represents a CAGR of -9.55% over 6 yearsThe P/E Ratio of OneSource Specialty Pharma Ltd changed from 0 on March 2021 to 0 on March 2026 . This represents a CAGR of 0.0% over 6 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 38682 crore on March 2026 . This represents a CAGR of 7.98% over 6 yearsThe Market Cap of OneSource Specialty Pharma Ltd changed from ₹ 20003 crore on March 2025 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 2 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 1031 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -5.51% The revenue of OneSource Specialty Pharma Ltd for the Mar '26 is ₹ 430.34 crore as compare to the Dec '25 revenue of ₹ 294.97 crore. This represent the growth of 45.89% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 386.88 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -8.2% The ebitda of OneSource Specialty Pharma Ltd for the Mar '26 is ₹ 94.05 crore as compare to the Dec '25 ebitda of ₹ 14.86 crore. This represent the growth of 532.91% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 277.86 crore over 8 quarters. This represents a CAGR of 23.45% The net profit of OneSource Specialty Pharma Ltd changed from ₹ -5.55 crore to ₹ 4.6 crore over 8 quarters. This represents a CAGR of NaN% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 95.44 % on March 2026 . This represents a CAGR of -6.42% over 6 yearsThe Dividend Payout of OneSource Specialty Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About OneSource Specialty Pharma Ltd

Onesource Specialty Pharma Limited was incorporated as a Private Limited Company, with the name and style of Inbiopro Solutions Private Limited' dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore.
The Company name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies.
The status of the Company was then converted from a Private Limited Company to a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021,.
Subsequently, the name was changed to its present Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh Certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or OneSource Specialty Pharma Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 35,925 Cr while Market cap of OneSource Specialty Pharma Ltd is 18,496 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd?

As of June 14, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2120.7. On the other hand, OneSource Specialty Pharma Ltd stock price is INR ₹1613.4.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and OneSource Specialty Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.